JP2014510082A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510082A5 JP2014510082A5 JP2013558307A JP2013558307A JP2014510082A5 JP 2014510082 A5 JP2014510082 A5 JP 2014510082A5 JP 2013558307 A JP2013558307 A JP 2013558307A JP 2013558307 A JP2013558307 A JP 2013558307A JP 2014510082 A5 JP2014510082 A5 JP 2014510082A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- item
- amino acid
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 84
- 150000001875 compounds Chemical class 0.000 claims description 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 11
- 102000000589 Interleukin-1 Human genes 0.000 claims description 10
- 108010002352 Interleukin-1 Proteins 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010003645 Atopy Diseases 0.000 claims description 4
- 208000009137 Behcet syndrome Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 239000000412 dendrimer Substances 0.000 claims description 4
- 229920000736 dendritic polymer Polymers 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000002314 neuroinflammatory effect Effects 0.000 claims description 3
- 230000014511 neuron projection development Effects 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 2
- 208000035939 Alveolitis allergic Diseases 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 208000028185 Angioedema Diseases 0.000 claims description 2
- 208000000104 Arthus reaction Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000027496 Behcet disease Diseases 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- 206010056979 Colitis microscopic Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010014666 Endocarditis bacterial Diseases 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 206010058838 Enterocolitis infectious Diseases 0.000 claims description 2
- 206010014950 Eosinophilia Diseases 0.000 claims description 2
- 208000027445 Farmer Lung Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 206010024229 Leprosy Diseases 0.000 claims description 2
- 241001442495 Mantophasmatodea Species 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 102000003945 NF-kappa B Human genes 0.000 claims description 2
- 108010057466 NF-kappa B Proteins 0.000 claims description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 208000003441 Transfusion reaction Diseases 0.000 claims description 2
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 230000002052 anaphylactic effect Effects 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000009361 bacterial endocarditis Diseases 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 208000013507 chronic prostatitis Diseases 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 208000022195 farmer lung disease Diseases 0.000 claims description 2
- 230000002949 hemolytic effect Effects 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 201000008269 immune-complex glomerulonephritis Diseases 0.000 claims description 2
- 201000008319 inclusion body myositis Diseases 0.000 claims description 2
- 208000027139 infectious colitis Diseases 0.000 claims description 2
- 201000007119 infective endocarditis Diseases 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 208000004341 lymphocytic colitis Diseases 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000007863 steatosis Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 claims description 2
- 239000013638 trimer Substances 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 230000005951 type IV hypersensitivity Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000005764 inhibitory process Effects 0.000 claims 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims 1
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- -1 tetramer Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 230000006576 neuronal survival Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170120 | 2011-03-14 | ||
| DKPA201170120 | 2011-03-14 | ||
| PCT/DK2012/000022 WO2012122985A1 (en) | 2011-03-14 | 2012-03-14 | Antagonists of the interleukin- 1 receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510082A JP2014510082A (ja) | 2014-04-24 |
| JP2014510082A5 true JP2014510082A5 (enExample) | 2015-04-23 |
| JP6120782B2 JP6120782B2 (ja) | 2017-04-26 |
Family
ID=45876525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558307A Active JP6120782B2 (ja) | 2011-03-14 | 2012-03-14 | インターロイキン−１受容体のアンタゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9359405B2 (enExample) |
| EP (1) | EP2686431B1 (enExample) |
| JP (1) | JP6120782B2 (enExample) |
| KR (1) | KR20140012127A (enExample) |
| CN (1) | CN103476933B (enExample) |
| AU (1) | AU2012228769B2 (enExample) |
| BR (1) | BR112013023309A2 (enExample) |
| CA (1) | CA2828504A1 (enExample) |
| ES (1) | ES2600616T3 (enExample) |
| MX (1) | MX2013010171A (enExample) |
| RU (1) | RU2013145283A (enExample) |
| WO (1) | WO2012122985A1 (enExample) |
| ZA (1) | ZA201306744B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2598526T3 (en) | 2010-07-29 | 2018-11-19 | Eleven Biotherapeutics Inc | CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS |
| KR102017026B1 (ko) * | 2013-01-10 | 2019-09-02 | (주) 수파드엘릭사 | 염증 또는 알러지의 예방 또는 치료용 약학 조성물 및 염증 또는 알러지 개선용 화장료 조성물 |
| CA2903706C (en) | 2013-03-13 | 2024-01-23 | Eleven Biotherapeutics, Inc. | Chimeric cytokine formulations for ocular delivery |
| JP2016520615A (ja) * | 2013-05-31 | 2016-07-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
| CN104711214B (zh) * | 2015-04-09 | 2019-02-12 | 武汉联程生物科技有限公司 | 一种大肠杆菌bbm2015001菌株及其用途 |
| WO2017063657A1 (en) | 2015-10-14 | 2017-04-20 | Phlogo Aps | Il1ra-derived peptide antagonist |
| KR20190117579A (ko) * | 2017-02-16 | 2019-10-16 | 엑스바이오테크, 인크. | 화농성 한선염의 치료 |
| EP3773678A4 (en) * | 2018-04-12 | 2022-05-04 | Mayo Foundation for Medical Education and Research | PROCEDURES FOR GUIDING TREATMENT DECISIONS IN USE |
| KR102022118B1 (ko) * | 2019-01-07 | 2019-09-18 | 주식회사 아스트로젠 | 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물 |
| WO2023284947A1 (en) | 2021-07-13 | 2023-01-19 | Phlogo Aps | Il1ra derived peptides for treatment of diabetic nephropathy |
| CN114177295B (zh) * | 2021-12-16 | 2023-09-19 | 上海市第五人民医院 | 白细胞介素1受体拮抗剂治疗非酒精性脂肪性肝病的应用 |
| CN116144668A (zh) * | 2023-02-13 | 2023-05-23 | 杭州吉倍思生物制药有限公司 | 人il-1r1基因、蛋白、同源二聚体蛋白质与用途 |
| AU2024255810A1 (en) * | 2023-04-14 | 2025-11-13 | Merck Sharp & Dohme Llc | A cyclic peptide for trapping interleukin-1 beta |
| WO2025101453A1 (en) * | 2023-11-07 | 2025-05-15 | University Of Washington | De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| KR970002917B1 (ko) | 1988-05-27 | 1997-03-12 | 씨네겐 인코포레이티드 | 인터루킨-i 억제제 |
| US6159460A (en) | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
| US6159937A (en) * | 1994-07-05 | 2000-12-12 | Steeno Research Group A/S | Immunomodulators |
| IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
| IT1270662B (it) | 1994-10-13 | 1997-05-07 | Applied Research Systems | Antagonista della interleuchina-1 |
| DE19919148A1 (de) * | 1999-04-27 | 2000-11-16 | Wieser Raimund J | Von Interleukin 12 abgeleitete Peptid-Homodimere und Peptid-Heterodimere |
| JP2004519230A (ja) * | 2001-02-06 | 2004-07-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 低減された免疫原性を有する修飾されたインターロイキン−１受容体アンタゴニスト（ｉｌ−１ｒａ） |
| EP1366455B1 (en) * | 2001-02-19 | 2008-07-02 | MERCK PATENT GmbH | Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity |
| AU2002332931A1 (en) | 2001-09-06 | 2003-03-24 | Board Of Regents, The University Of Texas System | Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor |
| WO2003102187A1 (en) * | 2002-05-31 | 2003-12-11 | Scegen Pty Ltd | Self-coalescing or self-aggregating proteins derived from a membrane translocating sequence |
| US20050159590A1 (en) | 2003-08-25 | 2005-07-21 | Galit Rotman | Variants of interleukin-1 receptor antagonist: compositions and uses thereof |
| US7482323B2 (en) | 2004-03-04 | 2009-01-27 | The University Of Tennessee Research Foundation | Intracellular interleukin-1 receptor antagonist and uses thereof |
| US7674464B2 (en) | 2004-03-04 | 2010-03-09 | The University Of Tennessee Research Foundation | Intracellular interleukin-1 receptor antagonists |
| ES2694252T3 (es) | 2004-04-02 | 2018-12-19 | Swedish Orphan Biovitrum Ab (Publ) | Métodos para reducir la agregación de IL-1ra |
| PL1751175T3 (pl) | 2004-05-05 | 2013-03-29 | Valorisation Recherche Soc En Commandite | Antagoniści receptora IL-1, kompozycje i sposoby leczenia |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| JP2008542685A (ja) | 2005-05-05 | 2008-11-27 | ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット | サイトカイン受容体修飾因子及びその使用 |
| US7736860B2 (en) | 2006-11-09 | 2010-06-15 | Univeristy Of Massachusetts | Methods of identifying compounds for the treatment of sterile inflammation |
| WO2009025763A2 (en) | 2007-08-16 | 2009-02-26 | Schepens Eye Research Institute | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| CN101889022A (zh) * | 2007-10-08 | 2010-11-17 | 阿纳福公司 | 三聚IL-1Ra |
| CN101255197B (zh) * | 2008-03-28 | 2012-01-25 | 浙江海正药业股份有限公司 | 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用 |
| WO2010091122A1 (en) * | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
-
2012
- 2012-03-14 RU RU2013145283/10A patent/RU2013145283A/ru not_active Application Discontinuation
- 2012-03-14 AU AU2012228769A patent/AU2012228769B2/en not_active Ceased
- 2012-03-14 KR KR1020137026679A patent/KR20140012127A/ko not_active Withdrawn
- 2012-03-14 BR BR112013023309A patent/BR112013023309A2/pt not_active IP Right Cessation
- 2012-03-14 EP EP12710122.8A patent/EP2686431B1/en active Active
- 2012-03-14 CN CN201280013172.1A patent/CN103476933B/zh not_active Expired - Fee Related
- 2012-03-14 WO PCT/DK2012/000022 patent/WO2012122985A1/en not_active Ceased
- 2012-03-14 CA CA2828504A patent/CA2828504A1/en not_active Abandoned
- 2012-03-14 ES ES12710122.8T patent/ES2600616T3/es active Active
- 2012-03-14 US US14/003,824 patent/US9359405B2/en active Active
- 2012-03-14 JP JP2013558307A patent/JP6120782B2/ja active Active
- 2012-03-14 MX MX2013010171A patent/MX2013010171A/es not_active Application Discontinuation
-
2013
- 2013-09-09 ZA ZA2013/06744A patent/ZA201306744B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510082A5 (enExample) | ||
| RU2013145283A (ru) | Новые антагонисты рецептора интерлейкина-1 | |
| JP7654587B2 (ja) | ペプチド組成物 | |
| Mwangi et al. | Antimicrobial peptides: new hope in the war against multidrug resistance | |
| Wen et al. | Shrimp MyD88 responsive to bacteria and white spot syndrome virus | |
| Onaga | Tachykinin: recent developments and novel roles in health and disease | |
| JP2011528332A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| Zhang et al. | Tongue sole (Cynoglossus semilaevis) prothymosin alpha: cytokine-like activities associated with the intact protein and the C-terminal region that lead to antiviral immunity via Myd88-dependent and-independent pathways respectively | |
| JPWO2019156137A5 (enExample) | ||
| Qi et al. | Molecular cloning, expression analysis and functional characterization of interleukin-22 in So-iny mullet, Liza haematocheila | |
| AR072524A1 (es) | Tratamiento de enfermedades inflamatorias con beta defensinas de mamiferos | |
| Conlon et al. | A family of antimicrobial and immunomodulatory peptides related to the frenatins from skin secretions of the Orinoco lime frog Sphaenorhynchus lacteus (Hylidae) | |
| JP2015164424A5 (enExample) | ||
| JP2016525095A5 (ja) | 環状ポリペプチド | |
| MX2010009373A (es) | Materiales biologicos y usos de los mismos. | |
| He et al. | Identification of SCARA3, SCARA5 and MARCO of class A scavenger receptor-like family in Pseudosciaena crocea | |
| JP2011528334A5 (enExample) | ||
| Luo et al. | ITLN in diploid hybrid fish (Carassius auratus cuvieri♀× Carassius auratus red var♂) is involved in host defense against bacterial infection | |
| CN101921314A (zh) | 脑靶向防治老年性痴呆的神经营养因子融合多肽 | |
| CN110590926B (zh) | 一种合方鲫itln蛋白及其制备方法和应用 | |
| Sorokina et al. | Autoantibodies to the α7 subunit of the neuronal acetylcholine receptor in craniocerebral trauma in children | |
| Yang et al. | LPS-induced TNFα factor (LITAF) in the snail Cipangopaludina chinensis: gene cloning and its apoptotic effect on NCI-H446 cells | |
| TW202304957A (zh) | Kv1.3阻斷劑 |